CD38 and Miyoshi myopathy: ASCT was also integral to the design of the CASSIOPEIA clinical trial, which led to the approval of the first daratumumab-based quadruplet as induction therapy in MM [4], and of the studies investigating other anti-CD38 MoAb-based therapies in the same setting [5,6,7,8,9].